(Q37966067)

26 August 2017

title

Pitavastatin: clinical effects from the LIVES Study (English)

1 reference

26 August 2017

Tamio Teramoto

1

1 reference

26 August 2017

publication date

1 November 2011

1 reference

26 August 2017

number of pages

4

1 reference

Atherosclerosis. Supplements

inferred from page(s)

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

285-288

1 reference

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Pitavastatin: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Pitavastatin: novel effects on lipid parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

The utility of observational studies in clinical decision making: lessons learned from statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Statins and metabolism of high density lipoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Statin safety: an assessment using an administrative claims database.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

HDL-C: role as a risk modifier

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970888-1

7 January 2021

10.1016/S1567-5688(11)70888-1

Identifiers

DOI

1 reference

26 August 2017

1 reference